Holen Sie sich die Stockscreener-App
13.05
11.88%
1.525
Schlusskurs vom Vortag:
$11.53
Offen:
$11.54
24-Stunden-Volumen:
290.65K
Relative Volume:
0.72
Marktkapitalisierung:
$700.39M
Einnahmen:
$2.22M
Nettoeinkommen (Verlust:
$-40.51M
KGV:
-10.16
EPS:
-1.2847
Netto-Cashflow:
$-46.53M
1W Leistung:
+16.85%
1M Leistung:
+13.26%
6M Leistung:
+24.16%
1J Leistung:
+0.00%
1-Tages-Spanne:
$11.44
$13.02
1-Wochen-Bereich:
$10.54
$12.91
52-Wochen-Spanne:
$5.14
$29.46
Upstream Bio Inc Stock (UPB) Company Profile
Firmenname
Upstream Bio Inc
Sektor
Branche
Telefon
781-208-2466
Adresse
890 WINTER STREET, SUITE 200, WALTHAM
Vergleichen Sie UPB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
UPB
Upstream Bio Inc
|
13.02 | 578.28M | 2.22M | -40.51M | -46.53M | -1.2847 |
|
VRTX
Vertex Pharmaceuticals Inc
|
475.19 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.50 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.19 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
588.61 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.06 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Upstream Bio Inc Stock (UPB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-05 | Eingeleitet | JP Morgan | Overweight |
| 2024-11-05 | Eingeleitet | Piper Sandler | Overweight |
| 2024-11-05 | Eingeleitet | TD Cowen | Buy |
| 2024-11-05 | Eingeleitet | William Blair | Outperform |
Upstream Bio Inc Aktie (UPB) Neueste Nachrichten
What drives Upstream Bio Inc. stock priceFree Market Dynamics Reports - jammulinksnews.com
What analysts say about Upstream Bio Inc. stockOutstanding capital returns - jammulinksnews.com
Is Upstream Bio Inc. a good long term investmentConsistent high-yield stocks - jammulinksnews.com
Upstream Bio Inc. Stock Analysis and ForecastHigh-performance investment picks - jammulinksnews.com
J.P. Morgan Maintains UpStream Bio(UPB.US) With Buy Rating - 富途牛牛
how upstream bio inc. stock performs during market volatilityFree Stock Market Insider Analysis - Newser
Upstream Bio, Inc. shares fall 4.98% premarket after HBM Healthcare Investments reports an 8.4% decline in NAV per share. - AInvest
What risks could impact Upstream Bio Inc. stock performanceHigh Potential Shares - Newser
Why Upstream Bio Inc. stock attracts strong analyst attentionHigh Return Conservative Stocks - Newser
How Upstream Bio Inc. stock performs during market volatilityFast Gains With Reduced Risk - Newser
Upstream Bio management to meet with Piper Sandler - TipRanks
What makes Upstream Bio Inc. stock price move sharplyFree VIP Investment Strategies - Newser
Will Q3 Shape Up To Be A VIBRANT Quarter For Upstream Bio? - RTTNews
Upstream Bio doses first patient in Phase 2 trial of verekitug in COPD - TipRanks
Upstream Bio, Inc. Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease - MarketScreener
Upstream Bio announces first patient dosed in phase 2 clinical trial of Verekitug - MarketScreener
Upstream Bio begins phase 2 COPD trial for verekitug - Investing.com
Upstream Bio Initiates Phase 2 VENTURE Trial for Verekitug in Moderate-to-Severe COPD, Expanding Its Respiratory Portfolio - Nasdaq
Upstream Bio Announces First Patient Dosed in Phase 2 - GlobeNewswire
Breakthrough COPD Drug Trial Launches with Unique 24-Week Dosing Schedule, Targeting 670 Patients - Stock Titan
Upstream Bio, Inc.(NasdaqGS: UPB) dropped from Russell 3000 Growth Index - MarketScreener
Rhumbline Advisers Has $82,000 Stock Position in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
Upstream Bio Plunges 11.54% Amid Clinical Trial Data Anticipation - AInvest
Upstream Bio, Inc.’s Verekitug: A Promising Contender in the TSLPR Antibody Space - TipRanks
Upstream Bio Stock Gets A Boost As New Lung Inflammation Drug Shows Higher Potency - Asianet Newsable
Upstream Bio announces presentation of data on verekitug’s TSLP receptor - TipRanks
Translational Data Illustrate a Mechanism of Greater - GlobeNewswire
Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor - The Manila Times
Upstream Bio Presents Pharmacology Modeling Data Supporting Verekitug's Potency over Tezepelumab at EAACI Congress - Nasdaq
Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor - GlobeNewswire Inc.
Bank of America Corp DE Takes Position in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
Upstream Bio Holds 2025 Annual Stockholders Meeting - TipRanks
Better Energy Stock: TotalEnergies vs. Chevron - The Globe and Mail
Upstream Bio (NASDAQ:UPB) Raised to Hold at Wall Street Zen - Defense World
Nuveen Asset Management LLC Takes Position in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
Upstream Bio, Inc. to Present TSLP Receptor Targeting Data for Verekitug at EAACI Congress 2025 - Nasdaq
Upstream Bio to Present Mechanistic Insights into - GlobeNewswire
Breakthrough: Upstream Bio's Verekitug Demonstrates Enhanced Potency Over Current Asthma Treatments - Stock Titan
Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - The Manila Times
Upstream Bio to Reveal Latest Inflammatory Disease Treatment Progress at Major Goldman Sachs Conference - Stock Titan
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Purchases New Position in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
Finanzdaten der Upstream Bio Inc-Aktie (UPB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Upstream Bio Inc-Aktie (UPB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | Director |
Oct 15 '24 |
Buy |
17.00 |
825,000 |
14,025,000 |
4,554,873 |
| AI Upstream LLC | 10% Owner |
Oct 15 '24 |
Buy |
17.00 |
1,175,000 |
19,975,000 |
1,175,000 |
3.26%
0.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):